Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07196462 · ClinicalTrials.gov registry record · NA

Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia

A NA study of Schizophrenia and Cannabis Use, sponsored by Vanderbilt University Medical Center.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT07196462: Recruiting NA study of Schizophrenia and Cannabis Use, sponsored by Vanderbilt University Medical Center.

NCT07196462 is a NA study of Schizophrenia and Cannabis Use that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 100 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07196462, a NA study of Schizophrenia and Cannabis Use, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cue-induced craving and cognitive performance in individuals with schizophrenia and schizoaffective disorder, while targeted stimulation of the L DLPFC leads to these changes in healthy controls who use cannabis. This study will test a model that integrates brain network pathophysiology and cognition to 1) explain the prevalence of cannabis use in schizophrenia and 2) identify a target for engagement in schizophrenia. This study seeks to establish a neuroscientific framework to guide future treatment-oriented studies aimed at reducing craving and improving cognitive performance in individuals with schizophrenia and schizoaffective disorder. This is a study of the effect of 2 rTMS interventions on functional connectivity and craving in individuals with schizophrenia or schizoaffective disorder and healthy controls who use cannabis. Aim 1: Target Engagement: Determine if rTMS manipulates functional connectivity of each target (DMN, L DLPFC) (n=100). Aim 2: Clinical Efficacy: Determine if rTMS affects cue-induced craving and if craving change correlates with change in functional connectivity (n=100). As an exploratory analysis, the factors that explain individual variance in rTMS-induced connectivity change will also be explored.

Primary Outcome

Cue-induced craving will be measured using a 0-10 Visual Analog Scale (VAS) before, during, and after in-scanner presentation of visual cannabis cues. Whole DMN and L DLPFC-left insula connectivity will be calculated.

Interventions

  • DEVICE 3 Minute iTBS to the L DLPFC
  • DEVICE One-Minute, Personalized, DMN Targeted CTBS

Study Locations (1)

Tennessee

  • Vanderbilt Psychiatric Hospital - Nashville

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2026-01-15
Est. Completion 2027-12-31
Phase NA

What NCT07196462 shows while recruiting

NCT07196462 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (54% lower).

The record links to 4 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which 3 Minute iTBS to the L DLPFC is the first listed.

NCT07196462 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT07196462 about?

NCT07196462 is a clinical study titled "Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia". The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitant...

What is the current status of trial NCT07196462?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-01-15. Estimated completion is 2027-12-31.

What conditions does trial NCT07196462 study?

This clinical trial studies the following conditions: Schizophrenia, Cannabis Use, Psychosis, rTMS.

What interventions are being tested in trial NCT07196462?

The interventions under investigation include: 3 Minute iTBS to the L DLPFC (DEVICE), One-Minute, Personalized, DMN Targeted CTBS (DEVICE).

Who is sponsoring clinical trial NCT07196462?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07196462 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07196462's enrollment target sits among peer trials

100 140th of 315 higher than 169 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01773278 · 100 participants · Phase 2

    Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07196462, the US trial registry maintained by the National Library of Medicine. NCT07196462 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.